MILLENIUM CONFERENCE ON NUCLEIC ACID THERAPEUTICS

核酸治疗千年会议

• 批准号: 6023979
• 负责人: ERIC WICKSTROM
• 金额: $ 0.55万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6023979
• 关键词: chronic disease /disorder; drug /agent; gene therapy; meeting /conference /symposium; microorganism disease chemotherapy; neoplasm /cancer chemotherapy; oligonucleotides; polynucleotides; transfection /expression vector; travel

A broad international research effort to develop nucleic acid analogs and vectors for treatment of cancers, chronic diseases, and microorganisms has reached the stage of clinical trials and the first FDA approval of a DNA drug. Great progress has occurred since the last Conference on Nucleic Acid Therapeutics in 1991. The 2000 meeting will provide a forum whereby the most recent developments in preparing gene specific drugs and vectors, and applying those agents in preclinical and clinical trials will be shared among scientists, clinicians, and regulators from around the world. Support is requested from NIH for a portion of the travel expenses of the 24 invited speakers. Funds for other expenses will be raised from interested vendors and pharmaceutical firms, as well as the International Union of Biochemistry and Molecular Biology. The conference follows the design of a Gordon Research Conference. Up to 300 participants will arrive on a Saturday, then attend six 20-minute talks during each morning and evening session on Sunday, Monday, and Tuesday. Oligonucleotide Derivatives, Diagnostic Oligonucleotide Chips, Mechanisms and Pharmacology, Preclinical Trials, Gene Therapy Vectors, and Clinical Trials will be discussed. Poster sessions will be held in the afternoons, leaving participants free to discuss mutual research interests and develop new projects. The cost of food is included in the registration fee. Most participants will stay at the conference hotel, and eat all their meals together. This meeting design encourages the maximum possible interaction of participants. The conference design, as well as the modest registration fee, hotel costs, and airfare will maximize the feasibility of attendance by young faculty, postdoctoral fellows, and graduate students. Speakers will be directed to present hard data from recent experiments, as opposed to illustrative presentations intended to persuade investors. There will be no special luncheons for speakers, no outside conference management firm, and no expensive banquet. Some of the funds raised will be utilized to make possible participation by promising young investigators who are unable to identify sufficient support for travel expenses. Through this design, the 2000 conference will stimulate new collaborations and potentiate new ideas by new and experienced investigators.

开发用于治疗癌症、慢性疾病和微生物的核酸类似物和载体的广泛国际研究工作已进入临床试验阶段，并且 FDA 首次批准了 DNA 药物。 自 1991 年上届核酸治疗会议以来，已经取得了巨大进展。2000 年会议将提供一个论坛，科学家们将在该论坛上分享制备基因特异性药物和载体以及在临床前和临床试验中应用这些药物的最新进展，来自世界各地的临床医生和监管机构。 请求 NIH 支持 24 名受邀演讲者的部分旅费。 其他费用的资金将从感兴趣的供应商和制药公司以及国际生物化学和分子生物学联盟筹集。该会议遵循戈登研究会议的设计。 周六将有多达 300 名参与者抵达，然后在周日、周一和周二的早晚会议上参加 6 场 20 分钟的演讲。 将讨论寡核苷酸衍生物、诊断寡核苷酸芯片、机制和药理学、临床前试验、基因治疗载体和临床试验。 海报会议将在下午举行，让参与者自由讨论共同的研究兴趣并开发新项目。 食物费用包含在注册费中。 大多数与会者将入住会议酒店，并一起用餐。 这种会议设计鼓励参与者进行尽可能多的互动。会议设计以及低廉的注册费、酒店费用和机票费用将最大限度地提高年轻教师、博士后和研究生参加的可行性。 演讲者将被要求展示最近实验的硬数据，而不是旨在说服投资者的说明性演示。 不会为演讲者举办特别的午餐会，不会有外部会议管理公司，也不会举办昂贵的宴会。 筹集到的部分资金将用于帮助那些无法找到足够的差旅费支持的有前途的年轻研究人员参与。 通过这种设计，2000 年的会议将激发新的和经验丰富的研究人员进行新的合作并强化新的想法。